Frost & Sullivan Independent Equity Research

BiolineRX is on track with its execution of multiple clinical development programs for the Company’s lead product – BL-8040; the company has sufficient cash until H1-2020; target price remains unchanged as company’s clinical development is in line with our expectations


Company: BioLineRx        

Sector: Pharmaceuticals

Report type: Q1-2018 and 12 months since Initiation Updates

For all past reports click here

Published on: 27 June, 2018